NICE's diagnostics guidance on tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) makes recommendations on tumour profiling tests for oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer.

This guidance will assess use of the tests for ER-positive, HER2-negative cancer that has spread to the lymph nodes (LN-positive early breast cancer). DG34 will be withdrawn and replaced with new guidance which will include recommendations on tumour profiling tests for LN-positive early breast cancer and the existing recommendations on tumour profiling tests for LN-negative early breast cancer.

 
 
Status In progress
Technology type Diagnostic
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process DAP

Provisional Schedule

Expected publication 03 January 2024

Project Team

Project lead Donna Barnes

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Timeline

Key events during the development of the guidance:

Date Update
29 November 2023 Committee meeting
08 November 2023 - 22 November 2023 Diagnostics consultation: 1
26 October 2023 Committee meeting
14 April 2023 Scope published
07 March 2023 - 21 March 2023 Draft scope consultation
30 January 2023 - 06 March 2023 Specialist committee member recruitment
30 January 2023 In progress. Topic launch
30 January 2023 Launch
25 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual